Cargando…
NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL
INTRODUCTION: The NovoTTF-100A System (NovoTTF™ Therapy, Optune®, Novocure Inc.) is approved for use as a combination therapy with adjuvant temozolomide after postoperative chemo-radiation for newly diagnosed supratentorial glioblastoma (GBM). In our experience, dermatologic adverse events (dAEs) du...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719341/ http://dx.doi.org/10.1093/noajnl/vdac167.073 |
_version_ | 1784843302220070912 |
---|---|
author | Fukai, Junya Seki, Kohei Sasaki, Takahiro Koyama, Yoshiki Nakao, Naoyuki |
author_facet | Fukai, Junya Seki, Kohei Sasaki, Takahiro Koyama, Yoshiki Nakao, Naoyuki |
author_sort | Fukai, Junya |
collection | PubMed |
description | INTRODUCTION: The NovoTTF-100A System (NovoTTF™ Therapy, Optune®, Novocure Inc.) is approved for use as a combination therapy with adjuvant temozolomide after postoperative chemo-radiation for newly diagnosed supratentorial glioblastoma (GBM). In our experience, dermatologic adverse events (dAEs) due to the continuous contact between the array and the scalp is not infrequently occurred, and we believe that the addition of skincare strategy is vital to maximize adherence to the NovoTTF™ Therapy. In Wakayama Medical University Hospital (WMUH), “WOC nurses,” certified Nurses in Wound, Ostomy and Continence Nursing, cooperate with neurosurgeons for the skincare of the patients.In this presentation, we review our dAE experience and introduce our skincare strategy by WOC nurse. METHODS: We collected and analyzed clinical information of GBM patients treated with NovoTTF™ Therapy in WHUH and focused on the dAEs of the patients. RESULTS: Total 7 patients (Male, 6; Female, 1). Median age, 64.4 (38-78). dAEs occurred in 6/7 cases (86%). dAEs includes contact dermatitis 5 (71%), erosion 3 (43%), ulcers 0, foliiculitis 3 (43%). CTCAE grading of dAEs, 1 or 2. Two cases (29%) abandoned NovoTTF™ Therapy due to dAEs. Based on our skincare strategy, which consists of three essential rules of scalp care (cleansing, moisturization, protection), WOC nurses have close contact with the patients and their caregivers from the beginning of the therapy. CONCLUSION: The addition of skincare strategies to the NovoTTF-100A System would be vital for the adherence to NovoTTF therapy, which contribute to the therapeutic benefit of the Therapy. Not only neurosurgeons and patients but also nurses and caregivers must cooperate in scalp care and dAE treatment. |
format | Online Article Text |
id | pubmed-9719341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97193412022-12-06 NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL Fukai, Junya Seki, Kohei Sasaki, Takahiro Koyama, Yoshiki Nakao, Naoyuki Neurooncol Adv Abstracts INTRODUCTION: The NovoTTF-100A System (NovoTTF™ Therapy, Optune®, Novocure Inc.) is approved for use as a combination therapy with adjuvant temozolomide after postoperative chemo-radiation for newly diagnosed supratentorial glioblastoma (GBM). In our experience, dermatologic adverse events (dAEs) due to the continuous contact between the array and the scalp is not infrequently occurred, and we believe that the addition of skincare strategy is vital to maximize adherence to the NovoTTF™ Therapy. In Wakayama Medical University Hospital (WMUH), “WOC nurses,” certified Nurses in Wound, Ostomy and Continence Nursing, cooperate with neurosurgeons for the skincare of the patients.In this presentation, we review our dAE experience and introduce our skincare strategy by WOC nurse. METHODS: We collected and analyzed clinical information of GBM patients treated with NovoTTF™ Therapy in WHUH and focused on the dAEs of the patients. RESULTS: Total 7 patients (Male, 6; Female, 1). Median age, 64.4 (38-78). dAEs occurred in 6/7 cases (86%). dAEs includes contact dermatitis 5 (71%), erosion 3 (43%), ulcers 0, foliiculitis 3 (43%). CTCAE grading of dAEs, 1 or 2. Two cases (29%) abandoned NovoTTF™ Therapy due to dAEs. Based on our skincare strategy, which consists of three essential rules of scalp care (cleansing, moisturization, protection), WOC nurses have close contact with the patients and their caregivers from the beginning of the therapy. CONCLUSION: The addition of skincare strategies to the NovoTTF-100A System would be vital for the adherence to NovoTTF therapy, which contribute to the therapeutic benefit of the Therapy. Not only neurosurgeons and patients but also nurses and caregivers must cooperate in scalp care and dAE treatment. Oxford University Press 2022-12-03 /pmc/articles/PMC9719341/ http://dx.doi.org/10.1093/noajnl/vdac167.073 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstracts Fukai, Junya Seki, Kohei Sasaki, Takahiro Koyama, Yoshiki Nakao, Naoyuki NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL |
title | NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL |
title_full | NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL |
title_fullStr | NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL |
title_full_unstemmed | NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL |
title_short | NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL |
title_sort | nqpc-9 characterization and management of dermatologic adverse events with optune® in wakayama medical university hospital |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719341/ http://dx.doi.org/10.1093/noajnl/vdac167.073 |
work_keys_str_mv | AT fukaijunya nqpc9characterizationandmanagementofdermatologicadverseeventswithoptuneinwakayamamedicaluniversityhospital AT sekikohei nqpc9characterizationandmanagementofdermatologicadverseeventswithoptuneinwakayamamedicaluniversityhospital AT sasakitakahiro nqpc9characterizationandmanagementofdermatologicadverseeventswithoptuneinwakayamamedicaluniversityhospital AT koyamayoshiki nqpc9characterizationandmanagementofdermatologicadverseeventswithoptuneinwakayamamedicaluniversityhospital AT nakaonaoyuki nqpc9characterizationandmanagementofdermatologicadverseeventswithoptuneinwakayamamedicaluniversityhospital |